BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2496-508. [PMID: 34051983 DOI: 10.1053/j.gastro.2021.04.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sieber A, Aberra FN, Bonhomme B, Mckeever L, Lewis JD. Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases. Dig Dis Sci. [DOI: 10.1007/s10620-021-07361-z] [Reference Citation Analysis]
2 Hong HS, Kim K, Oh K, Lee JY, Hong SW, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn's disease: a retrospective study. Therap Adv Gastroenterol 2021;14:17562848211043017. [PMID: 34539814 DOI: 10.1177/17562848211043017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hong SJ, Galati J, Katz S. Crohn's Disease of the Elderly. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.014] [Reference Citation Analysis]
4 Becker HEF, Penders J, Jonkers DMAE. Microbial Metabolism of Inflammatory Bowel Disease Drugs: Current Evidence and Clinical Implementations. Gastroenterology 2021:S0016-5085(21)03488-0. [PMID: 34508777 DOI: 10.1053/j.gastro.2021.07.050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rolak S, Kane SV. Conventional Therapies for Crohn's Disease. Gastroenterol Clin North Am 2022;51:271-82. [PMID: 35595414 DOI: 10.1016/j.gtc.2021.12.004] [Reference Citation Analysis]
6 Meserve J, Singh S. Editorial: risk of pneumonia in IBD-reading between the lines! Aliment Pharmacol Ther 2021;54:1490-1. [PMID: 34741329 DOI: 10.1111/apt.16655] [Reference Citation Analysis]
7 Ahuja D, Singh S. Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice. Curr Opin Gastroenterol 2022;38:337-46. [PMID: 35762693 DOI: 10.1097/MOG.0000000000000854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Greer MC, Taylor SA. Perianal Imaging in Crohn Disease: Current Status With a Focus on MRI, From the AJR Special Series on Imaging of Inflammation. AJR Am J Roentgenol 2021. [PMID: 34549607 DOI: 10.2214/AJR.21.26615] [Reference Citation Analysis]
9 Abdullah I, Alhendi G, Alhadab A, Alasfour H, Shehab M. Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:725512. [PMID: 34660635 DOI: 10.3389/fmed.2021.725512] [Reference Citation Analysis]
10 Elhag DA, Kumar M, Saadaoui M, Akobeng AK, Al-mudahka F, Elawad M, Al Khodor S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. IJMS 2022;23:6966. [DOI: 10.3390/ijms23136966] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hart L, Verburgt CM, Wine E, Zachos M, Poppen A, Chavannes M, Van Limbergen J, Pai N. Nutritional Therapies and Their Influence on the Intestinal Microbiome in Pediatric Inflammatory Bowel Disease. Nutrients 2021;14:4. [PMID: 35010879 DOI: 10.3390/nu14010004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Sands BE, Irving PM, Hoops T, Izanec JL, Gao L, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, Afzali A, Aitova L, Aldeguer i Mante X, Allez M, Altorjay I, Argüelles Arias F, Armuzzi A, Augustyn M, Bafutto M, Barrio J, Begun J, Behrend C, Bezemer G, Bonnaud G, Brankovic M, Byung IJ, Calvet Calvo X, Chachu K, Chebli JMF, Cheon JH, Cichoz-lach H, Clark L, Cummings F, Dalal K, Danese S, De Boer N, De Lourdes Ferrari M, Désilets E, Dugalic P, Duvall G, Fedorishina O, Filip R, Flores C, Fogel R, Fon J, Frankel M, Friedenberg K, Fries W, Galina V, Gietka P, Goel R, Hasselblatt P, Herfarth H, Herszényi L, Hindryckx P, Hoentjen F, Horjus Talabur Horje C, Iduru S, Irving P, Isfort R, Jairath V, Jones M, Kalimullina D, Katz J, Kaur M, Khurana SK, Kim JS, Kim Y, Kleczkowski D, Knezevic S, Knoll A, Korman LY, Kotzev I, Kulyapin A, Lee KM, Leemreis D, Leszczyszyn J, Limdi J, Lissauer J, Loftus E, Malecka-panas E, Marshall J, Mihály E, Milan L, Monteleone G, Nagorni A, Owczarek D, Palekar N, Panaccione R, Park YS, Park SH, Parra R, Patai Á, Patel K, Patel B, Pershko A, Petrova E, Pineton de Chambrun G, Randall C, Riestra Menendez S, Ritter T, Rivero M, Roblin X, Rocca R, Romatowski J, Rydzewska G, Saibeni S, Salzberg B, Sarles H, Saunders J, Savarino EV, Serclova Z, Shchukina O, Siegel J, Soofi N, Sparrow M, Stokesberry D, Suiter D, Svorcan P, Tkachev A, Tsonev N, Tünde K, Ulbrych J, Vanasek T, Varga M, Vermeire S, Vicente Lidon R, Weiss ML, Wesley E, Winstead N, Wojcik K, Wypych J, Zaltman C, Zdena Z. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet 2022;399:2200-11. [DOI: 10.1016/s0140-6736(22)00688-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kim M, Jeon J. Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. IJMS 2022;23:2846. [DOI: 10.3390/ijms23052846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Oskouei ST, Kusmierczyk AR. Biosimilar Uptake: The Importance of Healthcare Provider Education. Pharmaceut Med 2021;35:215-24. [PMID: 34420201 DOI: 10.1007/s40290-021-00396-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Reference Citation Analysis]
16 El-Nakeep S, Shawky A, Abbas SF, Abdel Latif O. Stem cell transplantation for induction of remission in medically refractory Crohn's disease. Cochrane Database Syst Rev 2022;5:CD013070. [PMID: 35556242 DOI: 10.1002/14651858.CD013070.pub2] [Reference Citation Analysis]
17 Tse CS, Dulai PS. Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease. Gastroenterol Clin North Am 2022;51:283-98. [PMID: 35595415 DOI: 10.1016/j.gtc.2021.12.005] [Reference Citation Analysis]
18 Chen L, Lu Z, Kang D, Feng Z, Li G, Sun M, Liu Z, Wu W, Fang L. Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease. Front Pharmacol 2022;13:913720. [DOI: 10.3389/fphar.2022.913720] [Reference Citation Analysis]
19 Tsai L, McCurdy JD, Ma C, Jairath V, Singh S. Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts. Inflamm Bowel Dis 2021:izab287. [PMID: 34792604 DOI: 10.1093/ibd/izab287] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Nishida A, Nishino K, Ohno M, Sakai K, Owaki Y, Noda Y, Imaeda H. Update on gut microbiota in gastrointestinal diseases. WJCC 2022;10:7653-64. [DOI: 10.12998/wjcc.v10.i22.7653] [Reference Citation Analysis]
21 Ho EY, Singh S, Terdiman JP. Providing the Best Care for Patients With Crohn's Disease: An Examination of the New AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2557-62. [PMID: 34051986 DOI: 10.1053/j.gastro.2021.04.024] [Reference Citation Analysis]
22 Cao D, Li W, Ji Y, Wang X, Cui Z. Efficacy and safety of FiLaC™ for perianal fistulizing Crohn's disease: a systematic review and meta-analysis. Tech Coloproctol 2022. [PMID: 35962294 DOI: 10.1007/s10151-022-02682-1] [Reference Citation Analysis]
23 Swier RM, Siebrasse A, Coscia E, Peery AF. Diet in Benign Colonic Disorders: A Narrative Review. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.03.010] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]